Adult Dosing
Treatment of metastatic breast cancer
- 60 mg PO qd
- Note: Continue treatment until disease progression is observed
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
See Supplemental Patient Information
- Torsade de pointes, syncope, seizure, and/or death may occur during the therapy as a result of prolongation of the QTc interval in a dose and concentration-related manner [US Black Box Warning]
- Avoid toremifene in patients with QT syndrome. Correct hypokalemia/hypomagnesemia before initiating toremifene and monitor periodically during therapy. Obtain baseline ECG and subsequent ECG as clinically indicated in patients at increased risk
- Fetal harm may occur when administered to a pregnant woman. Women should be advised not to become pregnant when taking therapy
- Concomitant use of toremifene and drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided [US Black Box Warning]
- Hypercalcemia and tumor flare may occur in some CA breast patients with bone metastases during the first weeks of treatment. Monitor closely and discontinue the therapy if severe hypercalcemia
- Women of childbearing potential should use effective nonhormonal contraception during therapy
- Avoid long term use in pre-existing endometrial hyperplasia
- Leukopenia and thrombocytopenia have also been reported rarely; monitor CBC, LFTs and serum calcium
Cautions: Use cautiously in
- Hepatic impairment
- Bone metastases
- Concurrent use of thiazide diuretics
- Concurrent use of drugs that inhibit or induce CYP3A4
- Concurrent use of warfarin
Supplemental Patient Information
- Instruct patient to contact their physician if vaginal bleeding occurs
- Instruct patients that therapy may cause fetal harm and increase the risk of pregnancy loss. Advise premenopausal women taking therapy to use nonhormonal contraception during treatment
- Advise patients to avoid eating foods that inhibit CYP3A4, such as grapefruit, because they may increase toremifene concentrations
Pregnancy Category:D
Breastfeeding: Safety unknown. Due to the potential for serious adverse reactions in nursing infants, manufacturer recommends discontinuation of nursing or discontinuation of drug, taking into account the importance of the drug to the mother.
Pricing data from www.DrugStore.com in U.S.A.
- Fareston 60 MG TABS [Bottle] (GTX)
30 mg = $852.98
90 mg = $2544.92
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: Fareston 60 MG Oral Tablet
Ingredient(s): Toremifene
Imprint: TO;60
Color(s): White
Shape: Round
Size (mm): 9.00
Score: 1
Inactive Ingredient(s): colloidal silicon dioxide / lactose / magnesium stearate / microcrystalline cellulose / povidone / sodium starch glycolate / starch
Drug Label Author:
GTx, Inc.
DEA Schedule:
Non-Scheduled
